Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05760144 · ClinicalTrials.gov registry record · Early Phase 1
Endometrial Biopsy in Progestin Contraceptive Users
A Early Phase 1 study of Contraception, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT05760144: Recruiting Early Phase 1 study of Contraception, sponsored by Oregon Health and Science University.
NCT05760144 is a Early Phase 1 study of Contraception that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 52 participants, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05760144, a Early Phase 1 study of Contraception, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to learn more about menstrual changes in progestin contraception users. The investigators are hoping to find out what changes in the endometrium lead to different bleeding patterns during the first year of progestin contraception use. Participants will choose to receive the contraceptive implant (Etonogestrel implant also called Nexplanon) or the contraceptive injectable (Depo-medroxyprogesterone acetate (DMPA) also called Depo-Provera) for up to 12 months. They will be asked to have 4 endometrial biopsies over the course of the study, as well as blood draws, physical exams, and pregnancy tests. Participants will also use a daily text message or email diary to report bleeding patterns. This study's plan is to comprehensively phenotype bleeding patterns and profile the entire endometrium using single-cell RNA seq data (sCRNAseq).
Primary Outcome
The proportion of participants who experienced endometrial changes, as defined by any changes in gene expression
Conditions Studied
Interventions
- DRUG DMPA
- DRUG Etonogestrel implant
Study Locations (1)
Oregon
- OHSU - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2026-11 |
| Phase | Early Phase 1 |
What NCT05760144 shows while recruiting
NCT05760144 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 2 interventions - of which DMPA is the first listed.
NCT05760144 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT05760144 about?
NCT05760144 is a clinical study titled "Endometrial Biopsy in Progestin Contraceptive Users". The purpose of the study is to learn more about menstrual changes in progestin contraception users. The investigators are hoping to find out what changes in the endometrium lead to different bleeding patterns during the first year of progestin contraception use. Participants will choose to receive t...
What is the current status of trial NCT05760144?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 52 participants. The study started on 2023-07-01. Estimated completion is 2026-11.
What conditions does trial NCT05760144 study?
This clinical trial studies the following conditions: Contraception.
What interventions are being tested in trial NCT05760144?
The interventions under investigation include: DMPA (DRUG), Etonogestrel implant (DRUG).
Who is sponsoring clinical trial NCT05760144?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05760144 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05760144's enrollment target sits among peer trials
52 50th of 72 higher than 21 of 72 other Contraception trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraception trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Inpatient Adolescent Contraception
COMPLETED · Early Phase 1
-
Oral Contraceptive Pill (OCP) Pharmacogenomics
RECRUITING · Phase 4
-
Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement
RECRUITING · Phase 4
-
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
RECRUITING · NA
-
Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements
RECRUITING · NA
-
Hormonal Contraception Access Through Pharmacist Prescribing Implementation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI